Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Sep 30, 2022 12:29pm
180 Views
Post# 34997784

RE:RE:RE:RE:RE:RE:Waiting to discuss P1 on Oct 13 will not be a good sign

RE:RE:RE:RE:RE:RE:Waiting to discuss P1 on Oct 13 will not be a good signIf you are asking for full phase 1b data before 10/13, you don't understand how this works. What exactly are you asking TH to release before 10/13? They could announce proof of concept. They could announce a protocol extension filing. They could tell us how many patients they have had in the trial. They could tell us anything they wanted to since it is an open label trial but that is not how things are typically done. So, what is it you want them to tell us?

Joemare wrote: They've had plenty of time to recruit, add sites, visit them, lead the sites, push the sites to recruit etc.
That's what a CEO and VP have to do. Not providing any P1 data between now and the 13th is a failure. If they have P1 data, it's material. They need to tell shareholders.
If they wait for the 13th, then whatever they will say will not in any way sustain an increase in shareprice.  It will be bla bla bla promises and excuses.     


<< Previous
Bullboard Posts
Next >>